Organization of outpatient care for patients with diabetes mellitus in the context of the COVID-19 pandemic using telemedicine technologies

The COVID-19 pandemic had a serious impact on global health and showed that the current state of most health systems in the world was not ready for such an emergency. During the pandemic, the provision of specialized planned medical care to patients with chronic diseases was suspended, and therefore telemedicine technologies for remote monitoring of patients began to be actively used in many countries of the world. In the Russian Federation, leading experts have issued organizational and methodological recommendations for the management of patients with diabetes and other chronic diseases during the COVID-19 pandemic. The measures taken by the government to provide medicines and prevent COVID-19 infection have allowed many patients with diabetes to observe a self-isolation regime. Meanwhile, there are data on the negative impact of self-isolation on the general condition of patients for various reasons: a decrease in the level of self-control and physical activity, a reduction in the volume of planned specialized medical care. Telemedicine technologies in the Russian Federation have been successfully used for remote monitoring of patients with mild and moderate severity of COVID-19. Currently, the widespread use of telemedicine and modern digital technologies, which proved their effectiveness during the pandemic in the treatment and control of diabetes, has not yet reached an optimal level. This review examines the possibilities of using telemedicine technologies for patients with diabetes, analyzes the experience of foreign countries and the Russian Federation in managing patients with diabetes during a pandemic, and analyzes the effectiveness of management measures to provide medical care to patients with diabetes.

1. www.who.int [Internet]. Weekly epidemiological update on COVID-19 - 15 February 2023 [cited 25.07.2023]. Available from: https://www.who.int/publications/m/item/weekly-epidemiologicalupdate-on-covid-19---15-february-2023

2. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines [Internet]. PubMed. Bethesda (MD): National Institutes of Health (US); 2021 [cited 2023 Feb 10]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK570371/

3. Kastora S, Patel M, Carter B, et al. Impact of diabetes on COVID-19 mortality and hospital outcomes from a global perspective: An umbrella systematic review and meta-analysis. Endocrinol Diabetes Metab. 2022;5(3):e00338. doi: https://doi.org/10.1002/edm2.338

4. Markova ТN, Ponomareva AA, Samsonova IV, et al. Risk factors for fatal outcome in patients with type 2 diabetes mellitus and a new coronavirus infection. Endocrinol News, Opin Train. 2022;11(1):8-16. (In Russ.). doi: https://doi.org/10.33029/2304-9529-2022-11-1-8-16

5. Dedov II, Mokrysheva NG, Shestakova MV, et al. Glycemia control and choice of antihyperglycemic therapy in patients with type 2 diabetes mellitus and COVID-19: a consensus decision of the board of experts of the Russian association of endocrinologists Diabetes Mellitus. 2022;25(1):27-49. (In Russ.). doi: https://doi.org/10.14341/DM12873

6. Antsiferov MB, Andreeva AV, Markova TN. Organizatsiya spetsializirovannoi meditsinskoi pomoshchi vzroslomu naseleniyu s sakharnym diabetom v usloviyakh novoi koronavirusnoi infektsii COVID-19. Metodicheskie rekomendatsii № 87. Moscow; 2020. (In Russ.).

7. Bornstein SR, Rubino F, Khunti K, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020;8(6):546-550. doi: https://doi.org/10.1016/S2213-8587(20)30152-2

8. Ranscombe P. How diabetes management is adapting amid the COVID-19 pandemic. Lancet Diabetes Endocrinol. 2020;8(7):571. doi: https://doi.org/10.1016/S2213-8587(20)30181-9

9. Korytkowski M, Antinori-Lent K, Drincic A, et al. A pragmatic approach to inpatient diabetes management during the COVID-19 pandemic. J Clin Endocrinol Metab. 2020;105(9):3076-3087. doi: https://doi.org/10.1210/clinem/dgaa342

10. Beran D, Aebischer Perone S, Castellsague Perolini M, et al. Beyond the virus: Ensuring continuity of care for people with diabetes during COVID-19. Prim Care Diabetes. 2021;15(1):16-17. doi: https://doi.org/10.1016/j.pcd.2020.05.014

11. World Health Organization. A Health Telematics Policy in Support of WHO’S Health-For-All Strategy for Global Development: Report of the WHO Group Consultation on Health Telematics 11-16 December, 1997. Geneva: World Health Organization; 1998.

12. www.who.int [Internet]. Digital Implementation Investment Guide (DIIG): Integrating Digital Interventions into Health Programmes [cited 25.07.2023]. Available from: https://www.who.int/publications/i/item/9789240010567

13. www.who.int [Internet]. WHO guideline: recommendations on digital interventions for health system strengthening [cited 25.07.2023]. Available from: https://www.who.int/publications/i/item/9789241550505

14. Ma Y, Zhao C, Zhao Y, et al. Telemedicine application in patients with chronic disease: a systematic review and meta-analysis. BMC Med Inform Decis Mak. 2022;22(1):105. doi: https://doi.org/10.1186/s12911-022-01845-2

15. Flodgren G, Rachas A, Farmer AJ, et al. Interactive telemedicine: effects on professional practice and health care outcomes. Cochrane Database Syst Rev. 2015;2016(12):3076-3087. doi: https://doi.org/10.1002/14651858.CD002098.pub2

16. Prikaz Ministerstva zdravookhraneniya RF ot 30 noyabrya 2017 g. № 965n «Ob utverzhdenii poryadka organizatsii i okazaniya meditsinskoi pomoshchi s primeneniem telemeditsinskikh tekhnologii» (In Russ.). Доступно по: https://minjust.consultant.ru/documents/38004. Ссылка активна на 09.02.2023.

17. Phillip M, Bergenstal RM, Close KL, et al. The digital/virtual diabetes clinic: The future is now-recommendations from an international panel on diabetes digital technologies introduction. Diabetes Technol Ther. 2021;23(2):146-154. doi: https://doi.org/10.1089/dia.2020.0375

18. Ferorelli D, Nardelli L, Spagnolo L, et al. Medical legal aspects of telemedicine in italy: application fields, professional liability and focus on care services during the COVID-19 health emergency. J Prim Care Community Health. 2020;11(12):215013272098505. doi: https://doi.org/10.1177/2150132720985055

19. portolano.it [Internet]. Telemedicine: The New National Guidelines — Portolano Cavallo [cited 2023 May 22]. Available from: https://portolano.it/en/newsletter/portolano-cavallo-inform-life-sciences/telemedicine-the-new-national-guidelines

20. Ohannessian R, Duong TA, Odone A. Global telemedicine implementation and integration within health systems to fight the COVID-19 pandemic: A call to action. JMIR Public Health Surveill. 2020;6(2):e18810. doi: https://doi.org/10.2196/18810

21. Brody JE. [Internet]. A Pandemic Benefit: The Expansion of Telemedicine. The New York Times [cited 2020 May 11]. Available from: https://www.nytimes.com/2020/05/11/well/live/coronavirus-telemedicinetelehealth.html

22. Hollander JE, Carr BG. Virtually perfect? Telemedicine for Covid-19. N Engl J Med. 2020;382(18):1679-1681. doi: https://doi.org/10.1056/NEJMp2003539

23. Vaccaro AR, Getz CL, Cohen BE, et al. Practice management during the COVID-19 pandemic. J Am Acad Orthop Surg. 2020;28(11):464-470. doi: https://doi.org/10.5435/JAAOS-D-20-00379

24. Kronenfeld JP, Penedo FJ. Novel Coronavirus (COVID-19): telemedicine and remote care delivery in a time of medical crisis, implementation, and challenges. Transl Behav Med. 2021;11(2):659-663. doi: https://doi.org/10.1093/tbm/ibaa105

25. Faruque LI, Wiebe N, Ehteshami-Afshar A, et al. Effect of telemedicine on glycated hemoglobin in diabetes: a systematic review and meta-analysis of randomized trials. CMAJ. 2017;189(9):E341-E364. doi: https://doi.org/10.1503/cmaj.150885

26. Bertuzzi F, Stefani I, Rivolta B, et al. Teleconsultation in type 1 diabetes mellitus (TELEDIABE). Acta Diabetol. 2018;55(2):185-192. doi: https://doi.org/10.1007/s00592-017-1084-9

27. Tchero H, Kangambega P, Briatte C, et al. Clinical effectiveness of telemedicine in diabetes mellitus: A meta-analysis of 42 randomized controlled trials. Telemed J E Health. 2019;25(7):569-583. doi: https://doi.org/10.1089/tmj.2018.0128

28. Salehi S, Olyaeemanesh A, Mobinizadeh M, et al. Assessment of remote patient monitoring (RPM) systems for patients with type 2 diabetes: a systematic review and metaanalysis. J Diabetes Metab Disord. 2020;19(1):115-127. doi: https://doi.org/10.1007/s40200-019-00482-3

29. ElSayed NA, Aleppo G, Aroda VR, et al. Improving care and promoting health in populations: Standards of care in diabetes-2023. Diabetes Care. 2023;46(S1):S10-S18. doi: https://doi.org/10.2337/dc23-S001

30. Zhai YK, Zhu WJ, Cai YL, et al. Clinical- and cost-effectiveness of telemedicine in type 2 diabetes mellitus: a systematic review and meta-analysis. Medicine (Baltimore). 2014;93(28):e312. doi: https://doi.org/10.1097/MD.0000000000000312

31. Eberle C, Stichling S. Impact of COVID-19 lockdown on glycemic control in patients with type 1 and type 2 diabetes mellitus: a systematic review. Diabetol Metab Syndr. 2021;13(1):95. doi: https://doi.org/10.1186/s13098-021-00705-9

32. Scoccimarro D, Giove G, Silverii A, et al. Effects of home confinement during COVID-19 outbreak on glycemic control in patients with type 2 diabetes receiving telemedicine support. Acta Diabetol. 2022;59(2):281-284. doi: https://doi.org/10.1007/s00592-021-01817-4

33. Luzi L, Carruba M, Crialesi R, et al. Telemedicine and urban diabetes during COVID-19 pandemic in Milano, Italy during lock-down: epidemiological and sociodemographic picture. Acta Diabetol. 2021;58(7):919-927. doi: https://doi.org/10.1007/s00592-021-01700-2

34. Faleh AlMutairi M, Tourkmani AM, Alrasheedy AA, et al. Costeffectiveness of telemedicine care for patients with uncontrolled type 2 diabetes mellitus during the COVID-19 pandemic in Saudi Arabia. Ther Adv Chronic Dis. 2021;12(12):204062232110425. doi: https://doi.org/10.1177/20406223211042542

35. M Tourkmani A, J ALHarbi T, Rsheed AM Bin, et al. The impact of telemedicine on patients with uncontrolled type 2 diabetes mellitus during the COVID-19 pandemic in Saudi Arabia: Findings and implications. J Telemed Telecare. 2023;29(5):390-398. doi: https://doi.org/10.1177/1357633X20985763

36. Gorbacheva AM, Logvinova OV, Mokrysheva NG. Clinical and demographic analysis of telemedicine «doctor-patient» consultations at the Endocrinology Research Centre. Problems of Endocrinology. 2022;68(3):4-15. (In Russ.). doi: https://doi.org/10.14341/probl13088

37. Danne T, Limbert C, Puig Domingo M, et al. Telemonitoring, telemedicine and time in range during the pandemic: Paradigm change for diabetes risk management in the Post-COVID future. Diabetes Ther. 2021;12(9):2289-2310. doi: https://doi.org/10.1007/s13300-021-01114-xT

38. Hartmann-Boyce J, Morris E, Goyder C, et al. Diabetes and COVID-19: Risks, management, and learnings from other national disasters. Diabetes Care. 2020;43(8):1695-1703. doi: https://doi.org/10.2337/dc20-1192

39. Weiqing W, Zhongyan S, Guang W. Expert recommendations for diabetes management in primary care during COVID-19 pandemic. Zhonghua Neifenmi Daixie Zazhi. 2020;(36):185-190.

40. Linong J, Guangwei L, Qiuhong G. Guidance on diabetes management in elderly during COVID-19 pandemic. Chin J Diabetes. 2020;(28):1-6.

41. Assessore M, Salute A, Valle D’aosta R, et al. Alla Cortese Attenzione degli Illustri Assessori [Internet] [cited 2023 Feb 10]. Available from: https://www.fand.it/wp-content/uploads/2020/04/Lett.AMD-SIDSIE-a-Reg.-x-teleassistenza.pdf

42. CoviDiab — the global registry of new-onset Covid-19 related diabetes [Internet]. Available from: https://covidiab.e-dendrite.com/introduction.html

43. Wake DJ, Gibb FW, Kar P, et al. Endocrinology in the time of COVID-19: Remodelling diabetes services and emerging innovation. Eur J Endocrinol. 2020;183(2):G67-G77. doi: https://doi.org/10.1530/EJE-20-0377

44. Giorgino F, Bhana S, Czupryniak L, et al. Management of patients with diabetes and obesity in the COVID-19 era: Experiences and learnings from South and East Europe, the Middle East, and Africa. Diabetes Res Clin Pract. 2021;172:108617. doi: https://doi.org/10.1016/j.diabres.2020.108617

45. El-Malky AM, Alharbi AS, Alsaqabi AM, et al. COVID-19 specialized diabetes clinic model for excellence in diabetes care: scientific perspective. Clinical Diabetology. 2020;9(4):208-211. doi: https://doi.org/10.5603/DK.2020.0032

46. Belkhadir J. COVID-19 and diabetes from IDF MENA region. Diabetes Res Clin Pract. 2020;166:108277. doi: https://doi.org/10.1016/j.diabres.2020.108277

47. Andrikopoulos S, Johnson G. The Australian response to the COVID-19 pandemic and diabetes – Lessons learned. Diabetes Res Clin Pract. 2020;165:108246. doi: https://doi.org/10.1016/j.diabres.2020.108246

48. diabetes.org [Internet]. COVID Fears Kept One in Five People With Diabetes Away From the Doctor During Pandemic | ADA [cited 25.07.2023]. Available from: https://diabetes.org/newsroom/pressreleases/2021/covid-fears-kept-1-in-5-people-with-diabetes-awayfrom-the-dr-during-pandemic

49. Papazafiropoulou A. Telemedicine and diabetes during the COVID-19 era. Arch Med Sci – Atheroscler Dis. 2022;7(1):131-135. doi: https://doi.org/10.5114/amsad/150506

50. Prikaz Ministerstva Zdravookhraneniya RF ot 19.03.2020 N 198n (red. ot 27.03.2020) «O vremennom poryadke organizatsii raboty meditsinskikh organizatsii v tselyakh realizatsii mer po profilaktike i snizheniyu riskov rasprostraneniya novoi koronavirusnoi infektsii COVID-19» (In Russ.). Доступно по: https://edu.rosminzdrav.ru/fileadmin/user_upload/specialists/COVID-19/Prikaz_Minzdrava_Rossii_ot_19.03.2020_N_198n__red._ot_27.03.2020g.__ver1.pdf. Ссылка активна на 09.02.2023.

51. Mokrysheva NG, Galstyan GR, Kirzhakov MA, et al. COVID-19 Pandemic and Endocrinopathies. Problems of Endocrinology. 2020;66(1):7-13. (In Russ.). doi: https://doi.org/10.14341/probl12376

52. Endokrinopatii i COVID-19. Neotlozhnye sostoyaniya, ikh profilaktika i lechenie. (In Russ.). Доступно по: https://www.endocrincentr.ru/sites/default/files/all/news2020/Koronavirus_epid_2020/COVID-19.pdf. Ссылка активна на 10.02.23.

53. Drapkina OM, Drozdova LY, Avdeev SN, et al. The outpatient medical care in patients with chronic diseases under dispensary supervision in the conditions of the COVID-19 pandemic. Temporary guidelines. Version 2. Cardiovascular Therapy and Prevention. 2021;20(8):3172. (In Russ.). doi: https://doi.org/10.15829/1728-8800-2021-3172

54. diabetoved.ru [Internet]. COVID-19. [cited 2023 Feb 10]. Available from: https://diabetoved.ru/temu/covid-19

55. Shkola diabeta — Gosudarstvennoe byudzhetnoe uchrezhdenie zdravookhraneniya goroda Moskvy “Endokrinologicheskii dispenser Departamenta zdravookhraneniya goroda Moskvy”. (In Russ.). Доступно по: http://endocrin-dispanser.ru/shkola-diabeta/. Ссылка активна на 10.02.2023.

56. www.youtube.com [Internet]. DiabetTV — YouTube. [cited 2023 Feb 22]. Available from: https://www.youtube.com/@diabettv9277

57. Mukhametzyanov A. M., Bakirov B. A., Kakaulin A. G, i dr. Mobil’nye vyezdnye mul’tidistsiplinarnye brigady: ikh stanovlenie i razvitie v period pandemii novoi koronavirusnoi infektsii COVID-19. Meditsinskii vestnik Bashkortostana. 2021;16(6):21-26. (In Russ.).

58. Moskovskie vrachi vyekhali v devyat’ regionov dlya pomoshchi v bor’be s COVID-19 — DZM. (In Russ.). Доступно по: https://mosgorzdrav.ru/ru-RU/news/default/card/6359.html. Ссылка активна на 06.02.23.

59. Powers AC, Aronoff DM, Eckel RH. COVID-19 vaccine prioritization for type 1 and type 2 diabetes. Lancet Diabetes Endocrinol. 2021;9(3):140-141. doi: https://doi.org/10.1016/S2213-8587(21)00017-6

60. Pozitsiya FGBU «NMITs endokrinologii» Minzdrava Rossii o neobkhodimosti vaktsinatsii bol’nykh sakharnym diabetom protiv novoi koronavirusnoi infektsii (In Russ). Доступно по: https://www.endocrincentr.ru/news/poziciya-fgbunmic-endokrinologii-minzdrava-rossii-o-neobhodimosti. Ссылка активна на 23.09.22.

61. ElSayed NA, Aleppo G, Aroda VR, et al. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2023. Diabetes Care. 2023;46(S1):s49-s67.2. doi: https://doi.org/10.2337/dc23-S004

62. Murashko MA, Drapkina OM. Organizational aspects of vaccination against a new coronavirus infection. National Health Care (Russia). 2021;2(1):5-11. (In Russ.). doi: https://doi.org/10.47093/2713-069X.2021.2.1.5-11

63. Shestakova MV, Vikulova OK, Elfimova AR, et al. Risk factors for COVID-19 case fatality rate in people with type 1 and type 2 diabetes mellitus: A nationwide retrospective cohort study of 235,248 patients in the Russian Federation. Front Endocrinol (Lausanne). 2022;13(S1):s49-s67.2. doi: https://doi.org/10.3389/fendo.2022.909874